In chronic obstructive pulmonary disease (COPD), one of the most important consequences of bronchial obstruction is the formation of pulmonary hypertension (РH) and chronic pulmonary heart. At present, the question of the effect of the Spiloto Respimat preparation on hemodynamics in the pulmonary artery basins has not been sufficiently studied. The purpose of this work is to study the effect of prolonged spin-relaxation on РH in COPD patients with prolonged use. 30 patients with the 3rd stage of РH were examined on the background of the main therapy with an inhalation drug with 2 doses once a day within 24 weeks. Using the scales (expressed cough, sputum, dyspnea, auscultatory changes in the lungs), the clinical status of the patients was assessed, ECG, lung radiography, spirometry, echocardiography, and quality of life evaluation were performed. Against the background of the 24-weeks treatment, the main symptoms of the disease decreased from 7.5 + 0.3 to 1.6 + 0.3 (p <0.05), a decrease in the mean pulmonary artery pressure from 32.4 + 0.8 Up to 23.3 ± 1.2 mm Hg. The quality of life of patients has improved on scales reflecting physical and mental health. Spiolo Respimat, as a variant of a long bronchodilation therapy, leads to a significant reduction in the pulmonary artery pressure and can be used in the treatment of РH in with patients COPD.
In chronic obstructive pulmonary disease (COPD), one of the most important consequences of bronchial obstruction is the formation of pulmonary hypertension (РH) and chronic pulmonary heart. At present, the question of the effect of the Spiloto Respimat preparation on hemodynamics in the pulmonary artery basins has not been sufficiently studied. The purpose of this work is to study the effect of prolonged spin-relaxation on РH in COPD patients with prolonged use. 30 patients with the 3rd stage of РH were examined on the background of the main therapy with an inhalation drug with 2 doses once a day within 24 weeks. Using the scales (expressed cough, sputum, dyspnea, auscultatory changes in the lungs), the clinical status of the patients was assessed, ECG, lung radiography, spirometry, echocardiography, and quality of life evaluation were performed. Against the background of the 24-weeks treatment, the main symptoms of the disease decreased from 7.5 + 0.3 to 1.6 + 0.3 (p <0.05), a decrease in the mean pulmonary artery pressure from 32.4 + 0.8 Up to 23.3 ± 1.2 mm Hg. The quality of life of patients has improved on scales reflecting physical and mental health. Spiolo Respimat, as a variant of a long bronchodilation therapy, leads to a significant reduction in the pulmonary artery pressure and can be used in the treatment of РH in with patients COPD.